Living Donor Protection Act (H.R. 2923 / S. 1384)
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act (H.R. 2940/S. 1355)
Appropriations-NIH, NIDDK, Kidney Research
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027)
The New Era for Preventing End-Stage Kidney Disease Act of 2023
The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323)
The Long COVID RECOVERY NOW Act (H.R. 1114)
The CARING for Social Determinants Act of 2023 (H.R. 1066)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Use of Salt Substitutes to Reduce the Sodium Content in Standardized Foods; Proposed Rule
Medicaid Program; Ensuring Access to Medicaid Services; Proposed Rule
Duration: November 30, 2015
to
present
General Issues: Health Issues
Spending: about $5,254,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Deborah Darcy Congressman Steven R. Rothman, June 2005-November 2005
Congressman Steve Israel, July 2002-June 2005
Congressman Mike Doyle, September 1999-April 2001
Holly Bode n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on May 8.
Original Filing: 301578970.xml
Lobbying Issues
Living Donor Protection Act (H.R. 2923 / S. 1384)
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act (H.R. 2940/S. 1355)
Appropriations-NIH, NIDDK, Kidney Research
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027)
The New Era for Preventing End-Stage Kidney Disease Act of 2023
The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323)
The Long COVID RECOVERY NOW Act (H.R. 1114)
The CARING for Social Determinants Act of 2023 (H.R. 1066)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Use of Salt Substitutes to Reduce the Sodium Content in Standardized Foods; Proposed Rule
Medicaid Program; Ensuring Access to Medicaid Services; Proposed Rule
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 24.
Original Filing: 301541728.xml
Lobbying Issues
Living Donor Protection Act (H.R. 2923 / S. 1384)
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act (H.R. 2940/S. 1355)
Appropriations-NIH, NIDDK, Kidney Research
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027)
The New Era for Preventing End-Stage Kidney Disease Act of 2023
The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323)
The Long COVID RECOVERY NOW Act (H.R. 1114)
The CARING for Social Determinants Act of 2023 (H.R. 1066)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Use of Salt Substitutes to Reduce the Sodium Content in Standardized Foods; Proposed Rule
Medicaid Program; Ensuring Access to Medicaid Services; Proposed Rule
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 18, 2023.
Original Filing: 301504655.xml
Lobbying Issues
Living Donor Protection Act (H.R. 2923 / S. 1384)
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act (H.R. 2940/S. 1355)
Appropriations-NIH, NIDDK, Kidney Research
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027)
The New Era for Preventing End-Stage Kidney Disease Act of 2023
The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323)
The Long COVID RECOVERY NOW Act (H.R. 1114)
The CARING for Social Determinants Act of 2023 (H.R. 1066)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Use of Salt Substitutes to Reduce the Sodium Content in Standardized Foods; Proposed Rule
Medicaid Program; Ensuring Access to Medicaid Services; Proposed Rule
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301491415.xml
Lobbying Issues
Living Donor Protection Act
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act
Medicaid
Appopriations-NIH, NIDDK, Kidney Research
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 21, 2023.
Original Filing: 301468370.xml
Lobbying Issues
Living Donor Protection Act
Medigap Expansion Act
CARE for All Kidneys Act
PASTEUR Act
Medicaid
Appopriations-NIH, NIDDK, Kidney Research
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 23, 2023.
Original Filing: 301444430.xml
Lobbying Issues
H.R. 8594/S. 4750, the Restore Protections for Dialysis Patients Act
H.R. 7845/ the NIH Clinical Trial Diversity Act
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
H.R. 4065/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2023, Labor-HHS-Education Appropriations Act
H.R. 7585, the Health Equity and Accountability Act of 2022 (HEAA)
H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
H.R. 7667, the Food and Drug Amendments of 2022
H.R. 7506, the New Era for Preventing End-Stage Kidney Disease Act of 2022
Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and Other Revisions to Medicare Enrollment and Eligibility Rules
Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry
Request for Information on ways to strengthen and improve the Organ Procurement and Transplantation Network
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301417393.xml
Lobbying Issues
H.R. 8594/S. 4750, the Restore Protections for Dialysis Patients Act
H.R. 7845/ the NIH Clinical Trial Diversity Act
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
H.R. 4065/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2023, Labor-HHS-Education Appropriations Act
H.R. 7585, the Health Equity and Accountability Act of 2022 (HEAA)
H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
H.R. 7667, the Food and Drug Amendments of 2022
H.R. 7506, the New Era for Preventing End-Stage Kidney Disease Act of 2022
Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and Other Revisions to Medicare Enrollment and Eligibility Rules
Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry
Request for Information on ways to strengthen and improve the Organ Procurement and Transplantation Network
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301395003.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
H.R. 4065/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2023, Labor-HHS-Education Appropriations Act
H.R. 7585, the Health Equity and Accountability Act of 2022 (HEAA)
H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
H.R. 7845, NIH Clinical Trial Diversity Act of 2022
H.R. 7667, the Food and Drug Amendments of 2022
H.R. 7506, the New Era for Preventing End-Stage Kidney Disease Act of 2022
Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and Other Revisions to Medicare Enrollment and Eligibility Rules
Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry
Request for Information on ways to strengthen and improve the Organ Procurement and Transplantation Network
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 21, 2022.
Original Filing: 301372693.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Increasing FMAP (Federal Medicare Assistance Percentage)
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations
Part D Payment Modernization (PDM) Model for plan year 2022
Charitable Premium Assistance
H.R. 3912/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2022, Labor-HHS-Education Appropriations Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301338700.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Increasing FMAP (Federal Medicare Assistance Percentage)
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations
Part D Payment Modernization (PDM) Model for plan year 2022
Charitable Premium Assistance
H.R. 3912/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2022, Labor-HHS-Education Appropriations Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301310058.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Increasing FMAP (Federal Medicare Assistance Percentage)
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations
Part D Payment Modernization (PDM) Model for plan year 2022
Charitable Premium Assistance
H.R. 3912/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2022, Labor-HHS-Education Appropriations Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301289873.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Increasing FMAP (Federal Medicare Assistance Percentage)
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations
Part D Payment Modernization (PDM) Model for plan year 2022
Charitable Premium Assistance
H.R. 3912/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021.
H.R. 3893, the CARE for All Kidneys Act
FY 2022, Labor-HHS-Education Appropriations Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265253.xml
Lobbying Issues
H.R. 1255/S. 377, the Living Donor Protection Act
H.R. 1676, the Jack Reynold Medigap Expansion Act
H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021
Increasing FMAP (Federal Medicare Assistance Percentage)
The American Rescue Plan Act of 2021
Health disparities
S. 1002, the Junk Plan Accountability and Disclosure Act of 2021
Expanding vaccine availability to dialysis patients
Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations
Part D Payment Modernization (PDM) Model for plan year 2022
Charitable Premium Assistance
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301245464.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
Funding for kidney disease research and KidneyX.
Banning surprise medical bills
Increasing the Medicaid Federal Medical Assistance Percentage (FMAP)
The Improving Social Determinants of Health Act of 2020
Funding for Racial and Ethnic Approaches to Community Health (REACH) program
Health Equity and Accountability Act
Reducing COVID-19 Disparities by Investing in Public Health Act
H.R. 8200, To Improve the health of minority individuals during the COVID-19 pandemic, and for other purposes.
Access to Genetic Counselor Services Act of 2019
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301223344.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
Funding for kidney disease research and KidneyX.
Banning surprise medical bills
Increasing the Medicaid Federal Medical Assistance Percentage (FMAP)
The Improving Social Determinants of Health Act of 2020
The Coronavirus Aid, Relief, and Economic Security (CARES) Act
The Families First Coronavirus Response Act
Paycheck Protection Program and Health Care Enhancement Act
Funding for Racial and Ethnic Approaches to Community Health (REACH) program
Health Equity and Accountability Act
Reducing COVID-19 Disparities by Investing in Public Health Act
H.R. 8200, To Improve the health of minority individuals during the COVID-19 pandemic, and for other purposes.
Access to Genetic Counselor Services Act of 2019
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301202303.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
Funding for kidney disease research and KidneyX.
Banning surprise medical bills
Increasing the Medicaid Federal Medical Assistance Percentage (FMAP)
The Improving Social Determinants of Health Act of 2020
The Coronavirus Aid, Relief, and Economic Security (CARES) Act
The Families First Coronavirus Response Act
Paycheck Protection Program and Health Care Enhancement Act
Funding for Racial and Ethnic Approaches to Community Health (REACH) program
Health Equity and Accountability Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 21, 2020.
Original Filing: 301180638.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
Funding for kidney disease research and KidneyX.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301126328.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
Funding for kidney disease research and KidneyX.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 18, 2019.
Original Filing: 301070835.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Advancing American Kidney Health
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 19, 2019.
Original Filing: 301050498.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Medicare Part D - Protected classes.
Living Donor Protection Act
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 23, 2019.
Original Filing: 301039052.xml
Lobbying Issues
Charitable premium assistance and reintroduction of the Access to Marketplace Insurance Act.
Notice of Benefit and Payment Parameters for 2020.
Medicare Part D - Protected classes.
Living Donor Protection Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301017148.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 1270, Living Donor Protection Act of 2017; kidney disease research.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 19, 2018.
Original Filing: 300991892.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 1270, Living Donor Protection Act of 2017; kidney disease research (H.R. 6157, the Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
American Kidney Fund amended a lobbying report for in-house lobbying in Q22018 on Oct. 15, 2018
Original Filing: 300985495.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; H.R. 1270, Living Donor Protection Act of 2017.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300978524.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; H.R. 1270, Living Donor Protection Act of 2017.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300952896.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; H.R. 1270, Living Donor Protection Act of 2017.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300928530.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act); H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; H.R. 1270, Living Donor Protection Act of 2017.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300912087.xml
Lobbying Issues
Charitable premium assistance (H.R. 3976, the Access to Marketplace Insurance Act)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 18, 2017.
Original Filing: 300886984.xml
Lobbying Issues
Charitable premium assistance (H.R. 3742 in the 114th Congress. Not yet reintroduced.)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300873826.xml
Lobbying Issues
Charitable premium assistance (H.R. 3742 in the 114th Congress. Not yet reintroduced.)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 19, 2017.
Original Filing: 300851117.xml
Lobbying Issues
H.R. 3742, the Access to Marketplace Insurance Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, American Kidney Fund had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300835622.xml
Lobbying Issues
H.R. 3742, the Access to Marketplace Insurance Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, American Kidney Fund had in-house lobbyists. The report was filed on July 19, 2016.
Original Filing: 300814731.xml
Lobbying Issues
H.R. 3742, the Access to Marketplace Insurance Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, American Kidney Fund had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300798870.xml
Lobbying Issues
H.R. 3742, the Access to Marketplace Insurance Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, American Kidney Fund had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779314.xml
Lobbying Issues
H.R. 3742, the Access to Marketplace Insurance Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
American Kidney Fund filed a lobbying registration on Jan. 6, 2016 for in-house lobbying efforts, effective Nov. 30, 2015.
Original Filing: 300769499.xml
Issue(s) they said they’d lobby about: Kidney disease legislation and insurance coverage legislation. H.R.3742, the Access to Marketplace Insurance Act. H.R. 1130/S.598, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...